Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
You may also be interested in...
A complex and weighty judgment from the High Court regarding a new class of anemia compounds tackles a range of thorny patent law issues including obviousness, insufficiency and indirect infringement.
The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.